



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_67976
Title of the Manuscript:	ASSESSMENT OF B-AESCIN EFFECT IN STREPTOZOTOCIN INDUCED DIABETIC MODEL: DIABETIC HEPATOTOXICITY STUDY
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<http://www.sciencedomain.org/journal/10/editorial-policy>)



[SDI Review Form 1.6](#)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>Change the tipe-2 diabetes classification to tipe-1 diabetes classification. The mechanism of streptozotocin is to promote selective toxicity by pancreatic beta cells. Thus insulin production declines dramatically, characterizing type-1 diabetes. Please read this paper to understand: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396517/</p> <p>So be careful with the type-2 diabetes references you used, because in this work you induced type-1 diabetes.</p> <p>In the introduction it is talked about hepatotoxicity of antidiabetic drugs, however they use a reference of a drug that has no antidiabetic action. Atorvastatin acts on cholesterol metabolism. So be careful what your text says and what the quote says (see Introduction line 2: ".....diagncosed in children. 1 Type 2.....")</p>	
Minor REVISION comments	<p>In the first sentence in the INTRODUCTION: "Hepatotoxicity of Antidiabetic Drugs." It's not customary to use a phrase as a subtitle for an introduction. Please review.</p> <p>Be careful with the term "kuffer cell". The correct is KUPFFER CELL.</p> <p>In the item: 2.6 Assessment of serum biochemical parameters – Please describe how the blood sample was collected, how it was centrifuged, how it was stored until the time of analysis.</p> <p>Please enter the Graph Pad Prism software version in 2.9.</p> <p>In the figure 2 and others: to monitor treatment it would be interesting to verify a statistical difference between the DM control group (without treatment) and the groups treated with b-aescin.</p> <p>In the Fig 5: The indicative arrows are not visible. Please highlight the markings better.</p> <p>I recommend enriching the discussion by talking about the action of b-aescin in the treatment of diabetes, as well as better discussing the doses used. The results allow for a better discussion.</p> <p>Enrich your conclusion.</p>	
Optional/General comments	<p>In the item 3.4 Alteration in serum biochemical parameters: the sentence "In previous literatures it was showed that mice were received single dose of STZ showed an increase in glucose, AST and ALT levels ^[12]. It was also revealed in the present study." Can be transfer to Discussion.</p>	

Commented [EMBHE1]: transfer to discussion



[SDI Review Form 1.6](#)

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<p><i>(If yes, Kindly please write down the ethical issues here in details)</i></p> <p>Yes, but all issues regarding the use of animals and ethics committee approval have been perfectly described.</p>	

Reviewer Details:

Name:	Edgar Matias Bach Hi
Department, University & Country	Lusíada University Center, Brazil